Aaron D. Viny

3.6k total citations
50 papers, 1.2k citations indexed

About

Aaron D. Viny is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Aaron D. Viny has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 24 papers in Hematology and 11 papers in Genetics. Recurrent topics in Aaron D. Viny's work include Acute Myeloid Leukemia Research (23 papers), Genomics and Chromatin Dynamics (14 papers) and Protein Degradation and Inhibitors (8 papers). Aaron D. Viny is often cited by papers focused on Acute Myeloid Leukemia Research (23 papers), Genomics and Chromatin Dynamics (14 papers) and Protein Degradation and Inhibitors (8 papers). Aaron D. Viny collaborates with scholars based in United States, Germany and Israel. Aaron D. Viny's co-authors include Ross L. Levine, Archie Bleyer, Ronald D. Barr, Jaroslaw P. Maciejewski, Swapna Thota, Barbara Spitzer, Alan Lichtin, Hideki Makishima, Ashwin Kishtagari and Brad Pohlman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Aaron D. Viny

47 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aaron D. Viny United States 15 546 462 273 201 192 50 1.2k
Philippe Mineur Belgium 18 400 0.7× 625 1.4× 638 2.3× 158 0.8× 191 1.0× 49 1.4k
Emma Das‐Gupta United Kingdom 18 425 0.8× 725 1.6× 180 0.7× 290 1.4× 201 1.0× 34 1.2k
Blythe Thomson United States 15 596 1.1× 538 1.2× 193 0.7× 375 1.9× 292 1.5× 39 1.7k
André Baruchel France 22 516 0.9× 757 1.6× 195 0.7× 650 3.2× 161 0.8× 45 1.7k
Uma Borate United States 14 200 0.4× 482 1.0× 171 0.6× 311 1.5× 101 0.5× 90 830
Thomas Cluzeau France 20 808 1.5× 1.4k 3.1× 569 2.1× 337 1.7× 329 1.7× 107 2.0k
Kendra Sweet United States 22 617 1.1× 1.1k 2.5× 604 2.2× 170 0.8× 191 1.0× 180 1.8k
Tamara Intermesoli Italy 17 127 0.2× 575 1.2× 331 1.2× 460 2.3× 178 0.9× 46 1.0k
Simone Ferrero Italy 18 347 0.6× 390 0.8× 270 1.0× 110 0.5× 91 0.5× 82 1.3k
J R Downing United States 15 519 1.0× 880 1.9× 161 0.6× 917 4.6× 105 0.5× 19 1.4k

Countries citing papers authored by Aaron D. Viny

Since Specialization
Citations

This map shows the geographic impact of Aaron D. Viny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron D. Viny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron D. Viny more than expected).

Fields of papers citing papers by Aaron D. Viny

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron D. Viny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron D. Viny. The network helps show where Aaron D. Viny may publish in the future.

Co-authorship network of co-authors of Aaron D. Viny

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron D. Viny. A scholar is included among the top collaborators of Aaron D. Viny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron D. Viny. Aaron D. Viny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tate, Tiffany, Hikmat Al‐Ahmadie, Xiao Chen, et al.. (2024). Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer. Nature Communications. 15(1). 6538–6538. 10 indexed citations
2.
Kubota, Yasuo & Aaron D. Viny. (2024). Germline predisposition for clonal hematopoiesis. Seminars in Hematology. 61(1). 61–67. 5 indexed citations
3.
Tolu, Seda S., Aaron D. Viny, Jennifer E. Amengual, Barbara Pro, & Susan E. Bates. (2024). Getting the right combination to break the epigenetic code. Nature Reviews Clinical Oncology. 22(2). 117–133. 6 indexed citations
4.
Bowman, Robert L., et al.. (2023). 3227 – STAG2-COHESIN LOSS ATTENUATES FLT3ITD MYELOID BLAST EXPANSION YET PRESERVES MUTANT HSCS. Experimental Hematology. 124. S163–S163. 1 indexed citations
5.
Bartholdy, Boris, Kith Pradhan, Tushar D. Bhagat, et al.. (2022). PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant Transformation. Blood Cancer Discovery. 3(5). 444–467. 11 indexed citations
6.
Meyer, Alison E., Cary Stelloh, Kirthi Pulakanti, et al.. (2022). Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML. Leukemia. 36(8). 2032–2041. 6 indexed citations
7.
Bansal, Kushagra, Daniel A. Michelson, Ricardo N. Ramírez, et al.. (2021). Aire regulates chromatin looping by evicting CTCF from domain boundaries and favoring accumulation of cohesin on superenhancers. Proceedings of the National Academy of Sciences. 118(38). 16 indexed citations
8.
Stahl, Maximilian, Kamal Menghrajani, Andriy Derkach, et al.. (2021). Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances. 5(5). 1552–1564. 108 indexed citations
9.
Smith, Catherine C., Aaron D. Viny, Evan Massi, et al.. (2021). Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical Cancer Research. 27(14). 4003–4011. 11 indexed citations
10.
Meyer, Alison E., et al.. (2021). A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML. Neoplasia. 23(3). 337–347. 14 indexed citations
11.
Rivas, Martín A., Ceyda Durmaz, Andreas Kloetgen, et al.. (2021). Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. Frontiers in Immunology. 12. 688493–688493. 6 indexed citations
12.
Ball, Brian, Meier Hsu, Sean M. Devlin, et al.. (2019). RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy. Blood. 134(Supplement_1). 18–18. 13 indexed citations
13.
Viny, Aaron D. & Ross L. Levine. (2017). Cohesin mutations in myeloid malignancies made simple. Current Opinion in Hematology. 25(2). 61–66. 20 indexed citations
14.
Galen, Peter van, Aaron D. Viny, Oren Ram, et al.. (2015). A Multiplexed System for Quantitative Comparisons of Chromatin Landscapes. Molecular Cell. 61(1). 170–180. 78 indexed citations
15.
Przychodzen, Bartlomiej, Xiaorong Gu, Dewen You, et al.. (2015). PHF6 - Somatic Mutations and Their Role in Pathophysiology of MDS and AML. Blood. 126(23). 1259–1259. 2 indexed citations
16.
Viny, Aaron D. & Ross L. Levine. (2014). Genetics of Myeloproliferative Neoplasms. The Cancer Journal. 20(1). 61–65. 40 indexed citations
17.
Viny, Aaron D., et al.. (2011). Description of two new MICA alleles: MICA*058 and MICA*002:03. Tissue Antigens. 79(2). 144–145. 1 indexed citations
18.
Viny, Aaron D., Michael J. Clemente, Monika Jasek, et al.. (2010). MICA polymorphism identified by whole genome array associated with NKG2D-mediated cytotoxicity in T-cell large granular lymphocyte leukemia. Haematologica. 95(10). 1713–1721. 16 indexed citations
19.
Viny, Aaron D., Alan Lichtin, Brad Pohlman, Thomas P. Loughran, & Jaroslaw P. Maciejewski. (2008). Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia. Leukemia & lymphoma. 49(5). 932–938. 62 indexed citations
20.
Subbiah, Vivek, Aaron D. Viny, Steven Rosenblatt, et al.. (2008). Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Experimental Hematology. 36(9). 1078–1083. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philippe Mineur Breakdown of academic impact, for papers by Emma Das‐Gupta Breakdown of academic impact, for papers by Blythe Thomson Breakdown of academic impact, for papers by André Baruchel Breakdown of academic impact, for papers by Uma Borate Breakdown of academic impact, for papers by Thomas Cluzeau Breakdown of academic impact, for papers by Kendra Sweet Breakdown of academic impact, for papers by Tamara Intermesoli Breakdown of academic impact, for papers by Simone Ferrero Breakdown of academic impact, for papers by J R Downing
Rankless by CCL
2026